Journal for ImmunoTherapy of Cancer (Nov 2020)
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
- Emmett Schmidt,
- Jonathan Thompson,
- Michael Chisamore,
- James Spicer,
- Åslaug Helland,
- Edurne Arriola,
- Manuel Dómine Gomez,
- Jose Manuel Trigo Perez,
- Ana Laura Ortega Granados,
- Noelly Madeleine,
- Austin Rayford,
- Katherine Lorens,
- Abdul Siddiqui,
- Hani Gabra,
- Jaya Nautiyal,
- David Micklem,
- James Lorens
Affiliations
- Emmett Schmidt
- Aff145 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA
- Jonathan Thompson
- Aff7 0000 0001 2111 8460grid.30760.32Medical College of Wisconsin 8701 W Watertown Plank Rd 53226 Milwaukee WI USA
- Michael Chisamore
- 2Merch and Co., Inc., Rahway, NJ, USA
- James Spicer
- 1King’s College London, Guy’s Hospital, London, UK
- Åslaug Helland
- 2Oslo University Hospital, Oslo, Norway
- Edurne Arriola
- 4Hospital del Mar, Barcelona, Spain
- Manuel Dómine Gomez
- 5Hospital Universitario Fundación Jiménez, Madrid, Spain
- Jose Manuel Trigo Perez
- 6Hospital Virgen de la Victoria, Málaga, Spain
- Ana Laura Ortega Granados
- 9Complejo Hospitalario de Jaén, Jaén, Spain
- Noelly Madeleine
- 12BerGenBio ASA, Bergen, Norway
- Austin Rayford
- 12BerGenBio ASA, Bergen, Norway
- Katherine Lorens
- 12BerGenBio ASA, Bergen, Norway
- Abdul Siddiqui
- 12BerGenBio ASA, Bergen, Norway
- Hani Gabra
- 12BerGenBio ASA, Bergen, Norway
- Jaya Nautiyal
- 12BerGenBio ASA, Bergen, Norway
- David Micklem
- 12BerGenBio ASA, Bergen, Norway
- James Lorens
- 12BerGenBio ASA, Bergen, Norway
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0362
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.
